文献速递性腺与生殖内分泌

TRAVERSE试验中睾酮替代疗法对性腺功能减退男性抑郁综合征的影响

Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

TRAVERSE心血管安全性试验的随机、安慰剂对照、双盲研究纳入5204例45至80岁性腺功能减退男性,评估1.62%经皮睾酮凝胶对抑郁症状的影响。2643例(50.8%)有显著抑郁症状,仅49例(1.5%)符合严格定义的晚发性低度持续性抑郁障碍(LG-PDD)。在有显著抑郁症状的男性及全部随机分组男性中,睾酮替代治疗与情绪和精力的小幅但显著改善相关,认知和睡眠质量无显著改善;在LG-PDD亚组中,任何结局指标均无显著差异,可能反映统计效能不足。

要点

  • 性腺功能减退中老年男性中显著抑郁症状常见(2643/5204,50.8%),但严格定义的LG-PDD不常见(49/5204,1.5%)。
  • 在有显著抑郁症状的男性及全部随机分组男性中,睾酮替代治疗与情绪和精力的小幅但显著改善相关。
  • 在LG-PDD亚组中,睾酮替代治疗与安慰剂在任何结局指标上均无显著差异,可能反映统计效能不足。

核心结论

  • 抑郁症状在性腺功能减退的中老年男性中常见,但LG-PDD不常见。
  • 睾酮替代治疗与有或无显著抑郁症状的性腺功能减退男性情绪和精力的小幅改善相关。

研究设计与样本

  • 随机、安慰剂对照、双盲研究,在316个试验中心开展。
  • 参与者为45至80岁男性,2次空腹睾酮水平低于300 ng/dL,有1个或以上性腺功能减退症状,且有心血管疾病(CVD)或CVD风险增加。
  • 评估3个亚组:严格定义的晚发性低度持续性抑郁障碍(LG-PDD,既往称「心境恶劣」)男性;所有有显著抑郁症状(患者健康问卷-9评分>4)的男性;所有随机分组男性。
  • 干预为1.62%经皮睾酮或安慰剂凝胶。

主要发现

  • 5204例随机分组参与者中,2643例(50.8%)有显著抑郁症状,仅49例(1.5%)符合LG-PDD的严格标准。
  • 在LG-PDD患者中,睾酮替代治疗组与安慰剂组在任何结局指标上均无显著差异,可能反映统计效能不足。
  • 在有显著抑郁症状的男性(n=2643)及全部随机分组参与者(n=5204)中,睾酮替代治疗与情绪和精力的小幅但显著更大改善相关,认知或睡眠质量无显著改善。

局限性

  • 在LG-PDD患者中,任何结局指标在睾酮替代治疗组与安慰剂组间均无显著差异,可能反映统计效能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The effect of testosterone on depressive symptoms in men with hypogonadism remains incompletely understood. OBJECTIVE: We assessed the effects of testosterone-replacement therapy (TRT) in improving depressive symptoms in hypogonadal men with and without depressive symptoms enrolled in the TRAVERSE cardiovascular safety trial. METHODS: A randomized, placebo-controlled, double-blind study was conducted at 316 trial sites. Participants included men, aged 45 to 80 years, with 2 fasting testosterone levels less than 300 ng/dL, 1 or more hypogonadal symptoms, cardiovascular disease (CVD), or increased risk of CVD. We evaluated 3 subgroups of participants: (1) men with rigorously defined, late-life-onset, low-grade persistent depressive disorder (LG-PDD, previously "dysthymia"); (2) all men with significant depressive symptoms (Patient Health Questionnaire-9 Score >4); and (3) all randomly assigned men. Intervention included 1.62% transdermal testosterone or placebo gel. Outcome measures included the proportions of participants (1) meeting criteria for LG-PDD or (2) with significant depressive symptoms; and changes in depressive symptoms, energy, sleep quality, and cognition in testosterone-treated vs placebo-treated men in the 3 subgroups. RESULTS: Of 5204 randomly assigned participants, 2643 (50.8%) had significant depressive symptoms, but only 49 (1.5%) met rigorous criteria for LG-PDD. Among those with LG-PDD, there was no significant difference in any outcome measure between the TRT and placebo groups, possibly reflecting low statistical power. In men with significant depressive symptoms (n = 2643) and in all randomly assigned participants (n = 5204), TRT was associated with modest but significantly greater improvements in mood and energy but not cognition or sleep quality. CONCLUSION: Depressive symptoms are common in middle-aged and older men with hypogonadism but LG-PDD is uncommon. TRT is associated with small improvements in mood and energy in hypogonadal men with and without significant depressive symptoms.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bhasin S, Seidman S, Travison TG, et al. Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy. J Clin Endocrinol Metab. 2024. PMID: 38205962. doi:10.1210/clinem/dgae026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。